Research programme: RAS pathway modulators - Sumitomo Pharma/Kobe University/KNC Laboratories
Latest Information Update: 05 Apr 2022
At a glance
- Originator KNC Laboratories; Kobe University
- Developer KNC Laboratories; Kobe University; Sumitomo Pharma
- Class Small molecules
- Mechanism of Action Ras signal transduction pathway modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer